IPO Update: August Had A Slow Start, But New US Filings Hint At Busy September
Executive Summary
There were only two biopharma IPOs in the US during August, bringing the year's total to 47. But with eight new filings in August, launches in September could rival July's total of nine first-time offerings, especially since this average return on this year's IPOs remains in positive territory.
You may also be interested in...
Finance Watch: Rough US Stock Market Doesn't Stop Biopharma IPOs As Six More Go Public
October has not been kind to biotech stocks, but that hasn't stopped drug developers from launching IPOs in the US. Also, Takeda reconfigures debt ahead of Shire deal and other offerings.
Bluebird Casts Wide Partnering Net To Keep Advancing Cell Therapy
Bluebird has been an active deal maker as it looks to add tools, targets and technological capabilities to its R&D engine. A pair of August TCR-focused deals, including the latest with Gritstone, continue that strategy.
Pipeline Watch: Phase III Starts In ALS And Lupus
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.